Anlotinib - Revision history

Lazy at 08:31, 18 January 2025

2025-01-18T08:31:49Z

← Older revision		Revision as of 01:31, 18 January 2025
Line 21:		Line 21:
	For more detailed information on anlotinib's clinical trial results and ongoing research, refer to the links provided.		For more detailed information on anlotinib's clinical trial results and ongoing research, refer to the links provided.
	\|links=https://www.cancernetwork.com/view/anlotinib-showed-efficacy-safety-patients-glioblastoma, https://www.sciencedirect.com/science/article/abs/pii/S0923753419305329, https://clinicaltrials.gov/ct2/results?cond=Glioblastoma&term=Anlotinib&cntry=&state=&city=&dist=		\|links=https://www.cancernetwork.com/view/anlotinib-showed-efficacy-safety-patients-glioblastoma, https://www.sciencedirect.com/science/article/abs/pii/S0923753419305329, https://clinicaltrials.gov/ct2/results?cond=Glioblastoma&term=Anlotinib&cntry=&state=&city=&dist=
	}}		\|overview=Anlotinib, a multi-target tyrosine kinase inhibitor currently under investigation and not yet FDA-approved, shows promise in treating various cancers, particularly Non-Small Cell Lung Cancer and Glioblastoma Multiforme, with early clinical trials suggesting potential improvements in overall and progression-free survival. While generally well-tolerated, common side effects include hypertension, fatigue, and hand-foot syndrome; ongoing research will further elucidate its efficacy and role in cancer treatment.}}

Lazy at 03:45, 14 June 2024

2024-06-14T03:45:28Z

← Older revision		Revision as of 20:45, 13 June 2024
Line 13:		Line 13:
	\|toxicity_level=3		\|toxicity_level=3
	\|toxicity_explanation=Generally well-tolerated but associated with some common side effects like hypertension and fatigue; ongoing trials will provide more detailed safety data for GBM		\|toxicity_explanation=Generally well-tolerated but associated with some common side effects like hypertension and fatigue; ongoing trials will provide more detailed safety data for GBM
	\|~~book_text~~=Anlotinib is a multi-target tyrosine kinase inhibitor (TKI) that targets receptors involved in tumor growth and angiogenesis, such as VEGFR, FGFR, PDGFR, c-Kit, and Ret. Developed by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., anlotinib has shown promise in treating various cancers including NSCLC, soft tissue sarcoma, and renal cell carcinoma. It works by inhibiting angiogenesis and tumor proliferation pathways, reducing tumor growth and spread.		\|notes=Anlotinib is a multi-target tyrosine kinase inhibitor (TKI) that targets receptors involved in tumor growth and angiogenesis, such as VEGFR, FGFR, PDGFR, c-Kit, and Ret. Developed by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., anlotinib has shown promise in treating various cancers including NSCLC, soft tissue sarcoma, and renal cell carcinoma. It works by inhibiting angiogenesis and tumor proliferation pathways, reducing tumor growth and spread.

	Preclinical studies have demonstrated that anlotinib can inhibit the growth of glioblastoma cells and reduce tumor angiogenesis. Clinical trials are ongoing to evaluate its safety and efficacy in patients with GBM. Initial findings suggest that anlotinib is well-tolerated and may provide benefits in controlling tumor growth and prolonging survival in patients with GBM.		Preclinical studies have demonstrated that anlotinib can inhibit the growth of glioblastoma cells and reduce tumor angiogenesis. Clinical trials are ongoing to evaluate its safety and efficacy in patients with GBM. Initial findings suggest that anlotinib is well-tolerated and may provide benefits in controlling tumor growth and prolonging survival in patients with GBM.

Lazy: Created page with "{{TreatmentInfo |drug_name=Anlotinib |FDA_approval=Under investigation; not yet FDA-approved |used_for=Various cancers including Non-Small Cell Lung Cancer (NSCLC), Soft Tissue Sarcoma, and Renal Cell Carcinoma; being investigated for Glioblastoma Multiforme (GBM) |clinical_trial_phase=Phase 2 and 3 (for different cancers); early-stage trials for GBM |common_side_effects=Hypertension, fatigue, hand-foot syndrome, diarrhea, proteinuria, thyroid dysfunction |OS_without=Med..."

2024-06-14T03:44:53Z

Created page with "{{TreatmentInfo |drug_name=Anlotinib |FDA_approval=Under investigation; not yet FDA-approved |used_for=Various cancers including Non-Small Cell Lung Cancer (NSCLC), Soft Tissue Sarcoma, and Renal Cell Carcinoma; being investigated for Glioblastoma Multiforme (GBM) |clinical_trial_phase=Phase 2 and 3 (for different cancers); early-stage trials for GBM |common_side_effects=Hypertension, fatigue, hand-foot syndrome, diarrhea, proteinuria, thyroid dysfunction |OS_without=Med..."

New page

{{TreatmentInfo
|drug_name=Anlotinib
|FDA_approval=Under investigation; not yet FDA-approved
|used_for=Various cancers including Non-Small Cell Lung Cancer (NSCLC), Soft Tissue Sarcoma, and Renal Cell Carcinoma; being investigated for Glioblastoma Multiforme (GBM)
|clinical_trial_phase=Phase 2 and 3 (for different cancers); early-stage trials for GBM
|common_side_effects=Hypertension, fatigue, hand-foot syndrome, diarrhea, proteinuria, thyroid dysfunction
|OS_without=Median overall survival for GBM is typically 15-17 months from diagnosis, or 8 months from recurrence
|OS_with=Preliminary data suggest potential improvement in overall survival, but specific figures for GBM are under investigation
|PFS_without=Data not specified
|PFS_with=Preliminary data suggest potential improvement in progression-free survival, but specific figures for GBM are under investigation
|usefulness_rating=4
|usefulness_explanation=Early clinical trials show promising results in improving overall survival and progression-free survival in various cancers, including potential benefits for GBM. Ongoing trials will provide more definitive data.
|toxicity_level=3
|toxicity_explanation=Generally well-tolerated but associated with some common side effects like hypertension and fatigue; ongoing trials will provide more detailed safety data for GBM
|book_text=Anlotinib is a multi-target tyrosine kinase inhibitor (TKI) that targets receptors involved in tumor growth and angiogenesis, such as VEGFR, FGFR, PDGFR, c-Kit, and Ret. Developed by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., anlotinib has shown promise in treating various cancers including NSCLC, soft tissue sarcoma, and renal cell carcinoma. It works by inhibiting angiogenesis and tumor proliferation pathways, reducing tumor growth and spread.

Preclinical studies have demonstrated that anlotinib can inhibit the growth of glioblastoma cells and reduce tumor angiogenesis. Clinical trials are ongoing to evaluate its safety and efficacy in patients with GBM. Initial findings suggest that anlotinib is well-tolerated and may provide benefits in controlling tumor growth and prolonging survival in patients with GBM.

Anlotinib is not yet FDA-approved and is currently available under investigation in clinical trials. Common side effects include hypertension, fatigue, hand-foot syndrome, diarrhea, proteinuria, and thyroid dysfunction. Further research and clinical data will help establish its role in the treatment of GBM and other cancers.

For more detailed information on anlotinib's clinical trial results and ongoing research, refer to the links provided.
|links=https://www.cancernetwork.com/view/anlotinib-showed-efficacy-safety-patients-glioblastoma, https://www.sciencedirect.com/science/article/abs/pii/S0923753419305329, https://clinicaltrials.gov/ct2/results?cond=Glioblastoma&term=Anlotinib&cntry=&state=&city=&dist=
}}